Rituximab in Neuromyelitis Optica Spectrum Disorders-Reply: Why Not as First-Line Therapy

Affiliations

¹ Institute of Neurology, Fondazione Policlinico Universitario "A. Gemelli," Catholic University, Rome, Italy.
² Institute of Neurology, Fondazione Policlinico Universitario "A. Gemelli," Catholic University, Rome, Italy2Don Gnocchi ONLUS Foundation, Milan, Italy.

Comment

Valentina Damato et al. JAMA Neurol. 2017.

. 2017 Apr 1;74(4):482-483.

doi: 10.1001/jamaneurol.2016.5936.

¹ Institute of Neurology, Fondazione Policlinico Universitario "A. Gemelli," Catholic University, Rome, Italy.
² Institute of Neurology, Fondazione Policlinico Universitario "A. Gemelli," Catholic University, Rome, Italy2Don Gnocchi ONLUS Foundation, Milan, Italy.

No abstract available

Comment on

Efficacy and Safety of Rituximab Therapy in Neuromyelitis Optica Spectrum Disorders: A Systematic Review and Meta-analysis.
Damato V, Evoli A, Iorio R. Damato V, et al. JAMA Neurol. 2016 Nov 1;73(11):1342-1348. doi: 10.1001/jamaneurol.2016.1637. JAMA Neurol. 2016. PMID: 27668357
Rituximab in Neuromyelitis Optica Spectrum Disorders: Why Not as First-Line Therapy.
Kim SH, Kim HJ. Kim SH, et al. JAMA Neurol. 2017 Apr 1;74(4):482. doi: 10.1001/jamaneurol.2016.5933. JAMA Neurol. 2017. PMID: 28166314 No abstract available.